This work presents simultaneous imaging and detection of three types of cell receptors using three types of plasmonic nanoparticles. The size, shape, and composition-dependent scattering profiles of these particles allow for a system of multiple distinct molecular markers using a single optical source. With this goal in mind, a system of tags consisting of anti-EGFR gold nanorods, anti-IGF1R silver nanospheres, and anti-HER-2 gold nanospheres was developed for monitoring the expression of three commonly overexpressed receptors in cancer cells. These labels were chosen because they each scatter strongly in a distinct spectral window. A hyperspectral dark-field microscope was developed to record the scattering spectra of cells labeled with these molecular tags. The ability to monitor multiple tags simultaneously may lead to applications such as profiling the immunophenotype of cell lines and gaining better knowledge of receptor signaling pathways. Single, dual, and triple tag experiments were performed to analyze the specificity of the nanoparticle tags as well as their effect on one another. While distinct resonance peaks in these studies show the ability to characterize cell lines using conjugated nanoparticles, shifts in these peaks also indicate changes in the cellular dielectric environment which may not be distinct from plasmon coupling between nanoparticles bound to proximal receptors.
Introduction
Multiplexed molecular imaging has been used in many applications over a wide range of imaging modalities. When used in in vitro studies, molecular imaging can aid in the understanding of cellular signaling pathways. This may lead to the development of new treatments for various diseases. When used in vivo, molecular imaging may be used for both diagnosis and as a tool to determine treatment. Detecting cancer cells which over-express certain receptors may lead to an early diagnosis before other changes in cellular structure arise. Also, cells with particular phenotypes may be resistant to certain drugs or therapies. Therefore, multiplexed molecular imaging may be used to determine the correct course of action during treatment 1 .Molecular imaging can also be an important tool for surgical resection of tumors. Many tumors have poorly defined borders preventing surgeons from removing the entire tumor without damaging normal tissues. This is quite dangerous during brain surgery, where the tumor may reside near vital brain regions or blood vessels. However, molecular imaging of receptors over-expressed by these tumors can allow the surgeon to see exactly where the tumor remains and remove it with minimal risk for the normal tissues. For these reasons, molecular imaging with various labels has been extensively.
While fluorescent molecules are the most commonly used molecular labels, they are mainly limited to visible wavelengths. This makes multiplexing more than seven fluorophores quite difficult. While the emission spectra of quantum dots may be extended into the NIR range, cytotoxicity issues prevent their widespread use for in vivo applications 2, 3 . Plasmonic nanoparticles provide as an alternative label that resolve these disadvantages. The peak scattering wavelength of these nanoparticles depends on their size, shape, and composition. By adjusting the aspect ratios of gold nanorods, their scattering peak may be shifted from 600nm to 2200nm. This alone extends the potential spectral range for multiplexing, while avoiding cytotoxicity issues 4 . Other nanoparticle types can supplement this range. Gold nanospheres scatter from 500nm to 600nm while silver nanospheres scatter from 400nm to 500nm. This wide range potentially allows for a much larger number of distinct labels in a multiplexed molecular imaging system. In this study, three plasmonic nanoparticle labels are used to simultaneously image different cellular receptors which are commonly over-expressed in cancer cells. Epidermal Growth Factor Receptor (EGFR), Human Epidermal growth factor Receptor 2 (HER-2), and Insulin-like Growth Factor 1 Receptor are specifically targeted in these experiments. Cells were chosen with different expression levels of these receptors to test for both the molecular specificity of the labels as well as the ability to determine cell immunophenotype by multiplexing the labels. A list of the cells used along with their ELISA measured receptor expression levels are presented in Table 1 . Table 1 : Cell lines used in the following experiments along with receptor expression levels measure using ELISA.
Distinct plasmonic tags are developed for each of the three targeted receptors. Gold nanorods with scattering above 600nm were conjugated to anti-EGFR antibodies. 60 nm gold nanospheres, with scattering peaks near 560nm, were conjugated to HER-2 mAb. Finally, 100nm silver nanospheres with scattering peaks near 530nm were conjugated to anti-IGF-1R antibodies.
The molecular specificity of each tag is confirmed with in vitro imaging and microspectroscopy analysis. Experiments with two and three simultaneous tags show the ability to determine immunophenotype. A shift in the scattering peaks observed in the multiple tag experiments versus the single tag experiments suggest either a change in the dielectric environment due to the cross talk between receptors, or plasmon coupling between particles bound to proximal receptors.
Methods

Nanoparticle-Antibody Conjugation
Gold nanorods were synthesized using established seed-mediated methods 5 . To an aqueous mixture of 7.5 mL of 0.1 M CTAB (Sigma-Aldrich, St. Louis, MO) and 0.250 mL of 0.01 M hydrogen tetrachloroaurate trihydrate (HAuCl 4 , Sigma-Aldrich, St. Louis, MO), 0.6 mL of ice cold 0.01 M sodium borohydride (Sigma-Aldrich, St. Louis, MO) was added under vigorous stirring to produce the gold seed, which was then gently heated and stirred for a few minutes. To a separate bottle containing 95 mL of 0.1 M CTAB in water at 29°C (Precision microprocessor-controlled 280 series water bath), 4 mL of 0.01 M HAuCl 4 , 0.6 mL of 0.01 M silver nitrate (Sigma-Aldrich, St. Louis, MO), and 0.64 mL of 0.1 M ascorbic acid (Sigma-Aldrich, St. Louis, MO) were added, and the mixture was swirled after the addition of each reactant. After the addition of 50 µL of gold seed, the bottle was capped, inverted five times, and incubated at 29°C overnight. The dimensions of the gold nanorods were measured at 67.1 ± 8.9 nm in length and 32.0 ± 6.1 nm in diameter (n=114) using TEM ( Tecnai G 2 Twin, FEI, Hillsboro, OR). Assuming a perfectly cylindrical nanorod shape, as well as the complete conversion of HAuCl 4 to Au, the concentration of the parent gold nanorod suspension was estimated to be 1.3⋅10 -10 M.
Gold nanorods were conjugated according to published procedures with anti-EGFR (E2156, clone 225, SigmaAldrich, St. Louis, MO, 1.56 mg/mL stock solution) or with mouse IgG 1 κ isotype control (16-4714-85 , eBioscience, 1.54 mg/mL stock solution) as a negative control, as follows: 1 mL of the gold nanorod suspension was centrifuged twice (10,000 RPM for 5 min.) and resuspended in 1 mL of 1 mM NaCl (8) . Polystyrene sulfonate (200 µL, 10 mg/mL in 1 mM NaCl, MW 18,000, Polysciences, Inc.) was added to the nanorods, and the suspension was placed on a shaker for 20 min. The nanorods were centrifuged at 10,000 RPM for 5 min. and resuspended in 1 mL of 20 mM HEPES pH 7.4. Four µL of 1.56 mg/mL mouse monoclonal anti-EGFR were added, and the suspension was placed on an oscillator for 30 min. Antibody concentrations were determined using an NanoDrop Spectrophotometer (ND1000, Nanodrop, Wilmington, DE). Optimal antibody concentration was determined by testing for suspension stability (i.e., least aggregation) under various amounts. The nanorods were centrifuged at 10,000 RPM for 5 min. and then finally resuspended in 0.5 mL of PBS containing 5 mg/mL BSA. This protocol is an adaptation of methods developed by the ElSayed group 6 .
Anti-IGF-1R nanosphere conjugates consist of 0.5 mL of 100 nm diameter silver colloid (15709-20SC, Ted Pella, Inc., Redding, CA) solution diluted with 485 μL of 20mM HEPES buffer and 16.1 μL of 1.40 mg/mLanti-IGF-1R (MS-301-PABX, ABD Serotec, Raleigh, NC) solution diluted with 62.5 μL of 20mM HEPES buffer. 100 nM K 2 CO 3 was used to adjust the pH of each solution to 7.0 ± 0.2. Solutions were then mixed on an oscillator for 20 minutes at 190 cycles/min. Following mixing, the solution was tested for antibody-nanoparticle conjugation by removing 100 μL and subsequent addition of 5 μL of 10% NaCl. Incomplete antibody coverage would result in a bluish color change due to particle aggregation. To prevent non-specific binding of proteins to remaining NP surface, 100 μL of 1% PEG (P2263, Sigma-Aldrich, St. Louis, MO) was added to the suspension and then allowed to interact. 15 minutes of centrifuging at 6000 RPM was used to remove excess PEG. Supernatant was removed, and the NP pellet was resuspended with 0.5 ml of PBS. These steps were then repeated to ensure complete removal of PEG, with minimal removal of NPs. This protocol is an adaptation of methods developed by the Richards-Kortum and Sokolov groups [7] [8] [9] . HER-2 mAb nanospheres were conjugated using the same method with 60nmgold spheres.
Cell Lines
EGFR (+) / IGF-1R(-) / HER-2(-)
MDA-MB-468 human breast adenocarcinoma were incubated at 37° C and 5% CO 2 using MEM Alpha Medium, with 10% fetal bovine serum 1% penicillin streptomycin [10] [11] [12] . HER-2(+) SK-BR-3 human breast adenocarcinoma were incubated at 37° C and 5% CO 2 using McCoy's 5A Medium Modified, with 10% fetal bovine serum 1% penicillin streptomycin 11, 13 . EGFR (+) / IGF-1R(low) / HER-2(low) expressing A549 human alveolar adenocarcinoma cells were incubated at 37° C and 5% CO 2 using F-12 Nutrient Mixture (Ham), 10% fetal bovine serum and 1% penicillin streptomycin. A second population of FACS selected high IGF-1R expressing A549 cells. A third population of A549 cells were additionally transfected with pcDNA 3.1 HER-2 and FACS selected for high HER-2 expression. EGFR (-) / IGF-1R(-) / HER-2(+) MDA-MB-453 human breast carcinoma cells were incubated at 37° C using Leibovitz L-15 Medium, with 10% fetal bovine serum and 1% penicillin streptomycin [11] [12] [13] . IGF-1R(low) / HER-2(-) MCF-7 human breast adenocarcinoma cells were incubated at 37° C and 5% CO 2 using MEM Alpha, 10% fetal bovine serum and 1% penicillin streptomycin 12, 14, 15 . IGF-1R(-) / HER-2(+) BT-474 human breast carcinoma cells were incubated at 37° C and 5% CO 2 using DMEM, 10% fetal bovine serum and 1% penicillin streptomycin 12, 14, 15 . EGFR (-) / IGF-1R(low) / HER-2(-) COLO-320DM human colon adenocarcinoma were incubated at 37° C and 5% CO 2 using RPMI Medium 1640, 10% fetal bovine serum and 1% penicillin streptomycin 11 . All cell lines were obtained from the ATCC through the Duke Cell Culture Facility.
Cell treatment
After overnight incubation of chambers plated with 80K cells, media was removed from cells designated for experiments. A solution consisting of 0.5 mL PBS / 5% FBS and 0.5 mL NP conjugate suspension was then added. Next, cells were incubated for 20 minutes, allowing for adequate interaction between conjugates and cells. After removal of the solution, cells were washed twice with media. In the case of dual and triple tag labeling, this procedure was then repeated with the addition NP conjugates. Experiments were then immediately conducted using the hyperspectral microscopy system.
Image Acquisition
A hyperspectral microscopy system previously developed 16 was used to conduct experiments on cells labeled with NP antibody conjugates. Hyperspectral data cubes were acquired from 450-700 nm, with individual images integrating for 30 ms. Each cell was imaged in a 170 x 170 pixel region of interest to minimize acquisition time. Two data cubes were acquired for each cell, with 5 and 1 nm increments, taking a total acquisition time of ~2.4 and ~12.0 s, respectively. Source-correction is performed by normalizing the signal by source intensity, as measured using a diffuse reflectance standard (WS-1, Ocean Optics, Dunedin, FL). Transmission experiments were conducted on both uncoated and immunolabeled conjugates using a spectrophotometer (Varian 300, Cary, Santa Clara, CA) with deuterium UV and mercury visible lamps.
Results
Anti-EGFR gold nanorods
The first set of experiments were performed to evaluate the molecular specificity of each of the labels. MDA-MB-468 cells which overexpress EGFR were incubated with the anti-EGFR gold nanorod conjugates [10] [11] [12] . Hyperspectral data cubes were recorded for individual cells. The distribution of the peak wavelengths of spectra averaged over each cell were fit to Gaussian distributions. This led to an average peak scattering wavelength of 664±9.3nm for anti-EGFR gold nanorods (N=139) (Figure 1 ).
Controls for this label included incubating EGFR non-expressing MDA-MB-453 cells to anti-EGFR gold nanorod conjugates 11, 12 , exposing MDA-MB-468 cells to gold nanorods conjugated with nonspecific IgG 1 monoclonal antibody, and MDA-MB-468 cells without any label. These control experiments showed insignificantscattering intensity compared to the experimental case (p<0.001), demonstrating the molecular specificity of the label. 
Anti-IGF-1R silver nanospheres
The molecular specificity of the anti-IGF-1R silver nanosphere label was tested with a similar procedure. A549 human alveolar adenocarcinoma cells over-expressing IGF-1R were incubated with the silver nanosphere tag 12, 17 .
Average scattering spectra recorded from the entire cell area were collected and fit to a Gaussian distribution. This showed an average scattering peak wavelength of 520.8±13.5nm (N=106) (Figure 2 ).
Controls for this label included incubating MDA-MB-468 human breast adenocarcinoma cells, which do not express IGF-1R 12, 18 , to the anti-IGF-1R silver nanosphere labels, incubating A549 cells with IgG 1 mAb silver nanospheres, and A549 cells without any labelThese control experiments showed insignificant scattering intensity compared to the experimental case (p<0.001), demonstrating the molecular specificity of the label. 
HER-2 mAb gold nanospheres
The molecular specificity of HER-2 mAb 60nm gold nanospheres was also tested. HER-2 overexpressing SK-BR-3 human breast adenocarcinoma cells were incubated with the HER-2 labels 11, 13 . Peak scattering distributions were fit with Gaussian distributions, indicating an average peak scattering wavelength of 587.0±11.9 nm (N=147) (Figure 3 ). 13, 15, 19 , incubating SK-BR-3 cells with IgG 1 mAb gold nanospheres, and SK-BR-3 cells with no label. These control experiments showed insignificantscattering intensity compared to the experimental case (p<0.001), demonstrating the molecular specificity of the label. 
Controls for this experiment included incubating HER-2 nonexpressing MDA-MB-468 human breast adenocarcinoma cells with HER-2 mAb nanospheres
EGFR and HER-2 Dual Labels
Following the tests for the molecular specificity of each individual label, tests were performed evaluating the effectiveness of dual tag systems. To test the immunophenotype indicating capabilities of the EGFR/HER-2 dual label, EGFR(+)/HER2(-) MDA-MB-468 cells were exposed to both the anti-EGFR nanorods and the HER-2 mAb gold nanospheres consecutively. These scattering spectra showed an average peak originating from the long axis of the nanorods [10] [11] [12] [13] 15, 19 . The same experiment with EGFR(-)/HER-2(+) MDA-MB-453 cells produced a peak associated with the HER-2 mAb conjugated gold nanospheres [11] [12] [13] . Although there was a slight redshift in this peak, most likely due to plasmonic coupling, it did not overlap with the scattering spectra from the nanorods. EGFR(-)/HER-2(-) COLO-320DM cell showed no significant scattering peaks 11 (data not shown).
To demonstrate dual labeling, , A549/HER-2 cells were tagged consecutively with anti-EGFR nanorods and anti-HER2 gold nanospheres. The anti-EGFR tag produced a peak scattering wavelength of 657.8±15.8nm (N=132) while the anti-HER2 tag produced a peak scattering wavelength of 551.4±8.6 (N=35). These two peaks showed significant statistical differences (p<0.001) when labeling the same cell simultaneously. 
EGFR and IGF-1R Dual Labels
The same types of experiments were performed for a dual EGFR/IGF-1R tag system. When exposed to anti-EGFR nanorods and IGF-1R silver nanospheres (in that order), EGFR(+)/IGF-1R(-) MDA-MB-468 cells showed a single scattering peak associated with the long axis of the nanorods [10] [11] [12] 19 . Also, EGFR(-)/IGF-1R(+) MDA-MB-453 cells showed a single scattering peak associated with the anti-IGF-1R conjugated nanospheres 12, 13 (data not shown).
Next, EGFR(+)/IGF-1R(+) A549 cells were tagged consecutively with anti-EGFR nanorods and anti-IGF-1R silver nanospheres.
The anti-EGFR label produced a peak scattering wavelength of 684.4nm±14.5nm (N=73) while the anti-IGF-1R label produced a peak scattering wavelength of 520.5±11.6nm(N=75). These two peak distributions were statistically significantly different (p<0.001).When compared to cells labeled individually with either the anti_EGFR or HER-2 mAb labels, a p value of <0.001 is determined for both labels. This signifies that there was a statistically significant change in the scattering peak distributions of either tag caused by the introduction of the second tag. . However, when the order of the two tags were reversed, the EGFR label produced a peak scattering wavelength of 643.0±5.3 nm (N=14), while the IGF-1R label produced a peak scattering wavelength of 523.1±6.9 nm (N=46). More interestingly, the peak distributions observed are much narrower compared to the distributions produced using the original labeling order. When compared to cells individually tagged with either the anti-EGFR or anti-IGF-1R labels, a p value=0.759 is determined for the IGF-1R label while a p value=0.201 is determined for the EGFR label. This shows that there is not a significant change in the peak scattering distributions of either tag caused by the introduction of the second tag. A significant reduction of scattering from the EGFR label is also observed when exposing the cells in this order. 
EGFR, HER-2, and IGF-1R Triple Label
For a final experiment, the immunophentype characterization potential of a three tag system was evaluated. To verify that A549/HER-2 cells, which are expected to express all three targeted receptors, were exposed to either anti-EGFR nanorods, anti-HER-2 gold nanospheres, or anti-IGF-1R silver nanospheres in individual labeling experiments. These experiments indicated an average scattering peak wavelength of 656.1±9.5nm (N=73) for the EGFR label, 521.8±7.9nm (N=75) for the IGF-1R label, and 542.7±21.3nm (N=75) for the HER-2 label. Each pairing of any two of these three distributions were statistically distinct (p<0.001), confirming the presence of all three targeted receptors (data not shown).
Next, the A549/HER-2 cells were exposed to the anti-EGFR nanorods, anti-IGF-1R silver nanospheres, and HER-2 mAb gold nanospheres consecutively. The anti-EGFR label produced a peak scattering wavelength of 661.3±12.7nm (N=127) while the HER-2 mAb label produced a peak scattering wavelength of 555.8 ±7.2nm (N=44). There was no discernible peak associated with the anti-IGF-1R label, expected to appear in the 500-550nm range. This is most likely due to the high expression of HER-2 leading to the masking of the IGF-1R scattering by the HER-2 scattering. Some individual cells did express enough IGF-1R to enable sufficient labeling to produce the scattering peak in the spectral data ( Figure 11 ) but it was not consistently observed. The two detectable peak distributions were determined to be statistically distinct (p<0.001). The peak scattering distributions from the individually labeled cells were compared to those from the cells tagged with all three labels. A p value of <0.001 was determined for the scattering associated with the anti-EGFR and HER-2 mAb labels. This is an intriguing contrast with the dual EGFR/HER-2 experiment, where no statistical significance was determined. 
Discussion
In this study, simultaneous imaging and analysis of three separate cellular receptors was shown. While previous studies used various nanorods of different aspect ratios to produce labels within separate spectral windows 4 , the use of different shapes and compositions of plasmonic nanoparticles allows for the further extension of spectral windows throughout the visible region. The use of three of these labels allows for immunophenotype characterization of three receptors overexpressed in many cancer cell lines. A lack of photobleaching and minimal cytotoxicity issues are major advantages of molecular imaging using plasmonic nanoparticles as opposed to organic fluorophores and quantum dots.
The experiements have shown the capabilities of dual labeling in determining the cell immunophenotype of two receptors. In cells expressing only one of the two targeted receptors, a single discernible peak distribution associated with the overexpressed receptor was observed. However, small peak distributions associated with the non-expressed receptor, were also. Since ELISA tests confirmed the immunophenotype of the chosen cell lines, these distributions are explained by minimal amounts of non-specific binding.
Cells expressing all targeted receptors were also exposed to both dual and triple labels. In these experiments, the scattering peak distributions for each receptor were statistically distinct (p<0.001) from the distributions for other receptors in both EGFR/HER-2 and EGFR/IGF-1R experiments. This indicates separation between the scattering windows of each tag. Furthermore, this allows the user visually assess the color of the nanoparticles within the cell. This capability could be exploited to allow for diagnosis based on receptor expression as well as potentially delineating malignant tumors within a surgical setting.
During the EGFR / IGF-1R dual label (original order) and the EGFR / IGF-1R / HER-2 triple label experiments, significant differences were determined between the scattering peak distributions of the individual label experiments when compared to the multiple label experiments. This indicates some slight change in the dielectric environment was caused by the introduction of the second or third label. This can be explained by a change in solute concentration which can influence dielectric environment or cross-talk between the activated receptors. Plasmonic coupling of particles bound to proximal receptors may also cause this difference. Further experiments with techniques such as polarization mapping may be necessary to separate changes due to dielectric medium alterations from changes due to plasmonic coupling 20 . In the EGFR/HER-2 and EGFR/IGF-1R experiments, peak scattering distributions were not statistically different when compared to the individual label trials. This indicates minimal change in the dielectric medium or minimal plasmonic coupling.
Data from the triple label experiments in indicates some degree of overlap of the peak scattering bands between the anti-IGF-1R and HER-2 mAb labels. This resulted in no observable scattering peak associated with the anti-IGF-1R for cells exposed to all three labels. The average peaks scattering wavelength of these two tags during individual labeling were only separated by 30nm. Furthermore, the lower level of IGF-1R expression in BT-474 cells allow the higher levels of scattering from the HER-2 mAb label to mask the signal associated with the anti-IGF-1R label. In future experiments, it will be necessary to choose labels with narrower spectral widths to avoid this overlap.
Reversing the order of labeling in the dual EGFR/IGF-1R label experiment produced an interesting change in the measured scattering distributions. This reverse order caused a significant decrease in the amount of scattering associated with the anti-EGFR tag. The experiments for both orders were performed consecutively from the same cell populations and nanoparticle batches. Images taken show a distinct difference in the number of bound anti-EGFR label when using the reverse order. A study by Desbois-Mouthon et al. 21 shows that the activation of IGF-1R leads to the release of amphiregulin, an EGFR-ligand, which binds to EGFR. It may be possible that a similar process occurs in these alveolar adenocarcinoma cells. Further research outside the scope of this work is necessary to understand this behavior.
Conclusion
In conclusion, this study has shown the ability to use three functionalized plasmonic nanoparticles to simultaneously image multiple cellular receptors. The spectral separation between the scattering peaks of these three labels allows for the characterization of cell immunophenotype. In some cases, statistically significant differences were detected between the scattering peak distributions of individual labels and the same labels used in dual and triple label experiments. This behavior is most likely due to either changes in the dielectric medium of the cell, reflecting receptor interactions, or plasmonic coupling between particles bound to proximal receptors, information that may also be used to better understand receptor dynamics. The ability to separate the effects of these two processes would lead to more advanced tools for intracellular biosensing applications.
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